- In December 2023, the U.S. Food and Drug Administration (FDA) approved Casgevy (exagamglogene autotemcel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics. It became the world’s first CRISPR-based gene therapy approved to treat sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). This groundbreaking approval marked a historic milestone in the CRISPR-edited stem cell therapy landscape
- In April 2024, Cellistic, a Belgian biotechnology firm, announced the acquisition of Artisan Bio’s STAR-CRISPR Cas12 platform. This strategic move allows Cellistic to offer more precise gene-editing tools for the development of induced pluripotent stem cell (iPSC)-derived allogeneic therapies, signaling growing commercial interest in CRISPR platforms
- In April 2025, researchers published new findings demonstrating a dual-tropic CRISPR-Cas9-based strategy that edits hematopoietic stem/progenitor cells to confer resistance against both R5 and X4 strains of HIV. This approach is seen as a promising potential treatment for long-term viral control in HIV-positive individuals
